$29.50
0.461.58%
At close: Aug 21, 5:00 PM EST
$30.02
0.521.76%
After Hours: 5:28 PM EST
ACADIA Pharmaceuticals Inc
ACADNASDAQ
ACADIA Pharmaceuticals Earnings & Forecasts
ACADIA Pharmaceuticals (ACAD) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
ACADIA Pharmaceuticals Guidance
ACADIA Pharmaceuticals (ACAD) last issued guidance on August 4, 2026 for fiscal year 2026. The company guided revenue in the range of $1.24B - $1.3B for the period.
Compared to prior guidance, ACADIA Pharmaceuticals raised its revenue forecast from a prior range of $1.22B - $1.28B.
ACADIA Pharmaceuticals has issued 15 guidance updates between November 2, 2022 and August 4, 2026. During this period, the company raised its outlook 6 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
Recent Earnings Results
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $0.04 | $0.07 | $0.13 | $0.14 |
| Actual | $0.18 | $0.02 | $0.14 | $0.26 |
| Surprise | +350.0% | -71.4% | +7.69% | +85.7% |
| Revenue | ||||
| Estimate | $295.2M | $280.6M | $292.5M | $275.4M |
| Actual | $308.0M | $268.1M | $284.0M | $278.6M |
| Surprise | +4.31% | -4.48% | -2.92% | +1.19% |
Analyst Estimates — Forward PeriodsSource: Wall Street consensus
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $0.19 | $0.22 | $0.15 | $0.16 |
| Revenue | ||||
| Consensus | $332.3M | $362.8M | — | — |
